Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Investor Presentation (August 2009)
24 slides from Glenmark Pharmaceuticals's investor presentation, August 2009
Slide 1: Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited August 2009
Slide 2: Agenda
Agenda GLENMARK GLENMARK :: TRACK TRACK RECORD RECORD BUSINESS BUSINESS OVERVIEW OVERVIEW INVESTMENT INVESTMENT HIGHLIGHTS HIGHLIGHTS ANNEXURE ANNEXURE 2
Slide 3: Glenmark: The Evolution
Glenmark : The Evolution Consolidated Turnover - Rs 1380 Mn Year 2000 2 Formulations Manufacturing Facilities Sales from International operations – 8% Initiation into NCE research Year 2009 Research Driven Global Integrated • Global Operations with more than 20 subsidiaries • 7 NCEs + NBEs in Clinic
Slide 4: A Track Record of Wealth Creation
A Track Record of Wealth Creation CAGR between 1st Jan '04-31st July '09 Total Income EBITDA Net Profit (Rs Mn) BSE Healthcare 7.60% 25,000 BSE Sensex 18.70% Glenmark (Adjusted Price) 39.30% 20,000 % 0 99~~4411% 4--0 R FFYY004 AGG R 15,000 nuueessCCA en RReevve 10,000 5,000 0 FY04 FY05 FY06 FY07 FY0
Slide 5: Agenda
Agenda GLENMARK GLENMARK :: TRACK TRACK RECORD RECORD BUSINESS BUSINESS OVERVIEW OVERVIEW INVESTMENT INVESTMENT HIGHLIGHTS HIGHLIGHTS ANNEXURE ANNEXURE 5 5
Slide 6: Company Overview
Company Overview GLENMARK GLENMARK Effective April 2008 GLENMARK GLENMARK PHARMACEUTICALS PHARMACEUTICALS LTD LTD GLENMARK GLENMARK GENERICS GENERICS LTDLTD (GGL) (GGL) DIVISIONS DIVISIONS (GPL) (A (GPL) (A subsidiary of the parent co.) subsidiary of the parent co.) •• Specialty/ Specialty/ Propriet
Slide 7: Glenmark Value Proposition
Glenmark Value Proposition GGL moving down the value GPL moving up the value chain chain in to Pure Generics & API Glenmark with Discovery research space Big pharma moving down the value chain by entering the Branded Generics & Pure Generics space API Pure Generics Branded Generics Proprietary Brand
Slide 8: Glenmark Pharmaceuticals Limited: Structure
Glenmark Pharmaceuticals Limited : Structure GPL Finished Dose Formulations R&D (Branded Generics) New Chemical Entities New Biological Entities Rest of the World European Union (NCE) (NBE) (RoW) GRC GRC 3886 3886 GBR GBR 500 500 India India Poland Poland GRC 8200 GRC 8200 GBR 600 GBR 600 Latin Lati
Slide 9: GPL: R & D Capabilities
GPL : R & D Capabilities Oglemilast: Oglemilast: Forrest Forrest Labs Labs Oglemilast: Oglemilast: Teijin Teijin Pharma Pharma Melogliptin: Melogliptin: Merck Merck KGaA KGaA GRC GRC 6211: 6211: Eli Eli Lilly Lilly 2004 2004 2005 2005 2006 2006 2007 2007 AA deal deal worth worth $190 $190 Mn Mn on o
Slide 10: Novel Drugs Pipeline
Novel Drugs Pipeline Pre Compound Primary Indications Target Clinicals Phasel Phase2 Phase3 Approval GRC 8200 Diabetes DPP IV (Melogliptin) Mellitus (Type II) Inhibitor GRC 3886 PDE IV Asthma, COPD (Oglemilast) Inhibitor Osteoarthritic Pain, TRPV1 GRC 6211 Neuropathic Pain, Antagonist Urinary Incont
Slide 11: Infrastructure focused on R&D
Infrastructure focused on R&D IPM, Regulatory, Clinical R&D – Global BD- USA Oxford UK Biologics R&D - Switzerland NCE R&D-India Establishing Global Centers of Excellence: • Small Molecule Research in India • Biologics Research in Switzerland • Clinical Research in Oxford – UK • Intellectual Propert
Slide 12: GPL: Specialty Business
GPL: Specialty Business GPL India India Semi Semi Regulated Regulated Markets Markets Latin Latin America America Europe Europe Growth Growth driven driven byby new new brand brand Russian Russian secondary secondary sales sales Brazil: Brazil: to to focus focus on on Focus Focus on on CNS CNS and a
Slide 13: GPL: Specialty Business Growth Drivers
GPL: Specialty Business Growth Drivers Russia CIS: Building on stronghold in Russia while increasing focus on 3 major CIS countries LatAm – Consolidation in Brazil and continuing activities in newer markets – Mexico, Venezuela, Peru India : Sharpening focus through divisional approach Africa-ME: Mak
Slide 14: Glenmark Generics Limited (GGL): Structure
Glenmark Generics Limited (GGL): Structure GGL Finished Dose Formulations API (Pure Play Generics) Argentina Global US EU (Oncology) 14
Slide 15: GGL: Growth Drivers
GGL: Growth Drivers GGL US US Europe Europe Latin Latin America America (Oncology) (Oncology) API API Portfolio Portfolio of of 46 46 generic generic Pursuing Pursuing multiple multiplerevenue revenue The The Oncology Oncology business business 41 41 DMFs DMFs filed filed till till March March 09 09
Slide 16: GGL: Generic Business Growth Drivers
GGL: Generic Business Growth Drivers Active Pharmaceutical Ingredients: • Continued expansion of API capabilities to support both internal and 3rd party dosage forms European Union: • Focus on difficult to develop molecules • Launched first product in the UK • Continued filings of DMFs across geogra
Slide 17: Glenmark Generics: FTF Opportunities
Glenmark Generics : FTF Opportunities Product Brand Name Plaintiff IMS Sales (year ending Mar 09) Ezetimibe Zetia Schering Plough USD 1.2 billion Trandolapril + Verapamil Tarka Abbott/ Sanofi- Aventis USD 72 million Fluticasone lotion 0.005% Cutivate Nycomed USD 37 million 17
Slide 18: Strategy: The Way Forward
Strategy : The Way Forward Research Research & & Development Development Branded Branded Generics Generics Pure Pure Generics Generics Advance Advance 22 NCEs NCEs (Oglemilast (Oglemilast and and Consolidate Consolidate Glenmark’s Glenmark’s position position Increase Increase presence presence in i
Slide 19: Agenda
Agenda GLENMARK GLENMARK :: TRACK TRACK RECORD RECORD BUSINESS BUSINESS OVERVIEW OVERVIEW INVESTMENT INVESTMENT HIGHLIGHTS HIGHLIGHTS ANNEXURE ANNEXURE 19 19
Slide 20: Why Glenmark: Investment Highlights
Why Glenmark : Investment Highlights Proven Proven Track Track Record Record Amongst Amongst the the best best NCE NCE pipeline pipeline in in the the country country Historical Historical Consolidated Consolidated Sales Sales have have grown grown at at aa Has Has recd recd ~~ USD USD 117 117 Mn Mn
Slide 21: Agenda
Agenda GLENMARK GLENMARK :: TRACK TRACK RECORD RECORD BUSINESS BUSINESS OVERVIEW OVERVIEW INVESTMENT INVESTMENT HIGHLIGHTS HIGHLIGHTS ANNEXURE ANNEXURE 21 21
Slide 22: Appendix: Manufacturing Facilities
Appendix: Manufacturing Facilities Have to highlight the latest inspections & the fact that GPL is one of the few big Generic Cos not to have recd a 483 1 dosage plant – Czech Republic 2 dosage plants - 1 API plant - HP, India Gujrat, India 1 dosage plant - Maharashtra, India 3 dosage plants - 1 dos
Slide 23: ANDA Filings
ANDA Filings Niche Area Focus in Filings ANDAs filed / marketed Till FY 0809 (Includes partner filings) Dermatology 18 Controlled Substance 6 Modified Release 2 Hormones 7 First to File (P-IVs) 9 Immediate Release 45 Total 87 23
Slide 24: Thank You
Thank You
Glenmark Pharmaceuticals — Investor Presentation (August 2009) on 6ix